Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trial Dropouts Illustrate Worries For J&J, Other Later Entrants To COVID Vaccine Space

Executive Summary

More than 5% of participants in J&J’s vaccine trial chose to be unblinded because they were eligible to receive a vaccine that had already gained a US FDA emergency use authorization.

You may also be interested in...



US FDA’s COVID Master Protocol Guidance To Maintain Influence Post-Pandemic

Agency seeking comment on document intended to replace the just-issued guidance on COVID-19 treatment development as FDA stresses the value of master protocols for developing clinical knowledge.

COVID-19 Vaccine Regulatory Strategy Evolving With The Pandemic

AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.

AstraZeneca COVID-19 Vaccine Data ‘Not Sufficient’ For Approval In Switzerland

Switzerland's medicines agency says it wants to see more data on AZD1222 before it can approve the vaccine. Also, a rolling review of Novavax's NVX-CoV2373, yet another COVID‑19 vaccine, is under way at the European Medicines Agency. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel